Navigation Links
Hormone Normalization Shows Encouraging Effects In Documented Clinically Deficient Men/Women
Date:10/15/2008

Nonprofit Cenegenics Education and Research Foundation partnered with two recognized professors from the University of Miami - Miller School of Medicine to examine testosterone and/or human growth hormone normalization in proven clinically deficient adults, reviewing effects on body composition and quality of life. Favorable findings from phase one of the three-phase study appear in the Journal of Multidisciplinary Healthcare, part of Dove Open Access.

Las Vegas, NV (PRWEB) October 15, 2008 -- Cenegenics® Medical Institute, global age management medicine leader, released encouraging findings from their study on testosterone and growth hormone normalization for documented clinically deficient adults, published in the Volume 2008 Journal of Multidisciplinary Healthcare, a peer-reviewed, online scientific journal of Dove Open Access. The study is called "Testosterone and growth hormone normalization: a retrospective study of health outcomes."

The findings are from phase one of the three-phase retrospective study, a collaboration between Cenegenics Education and Research Foundation (CERF) and two recognized professors from the University of Miami - Miller School of Medicine: Enrique Ginzburg, MD, FACS, and Nancy Klimas, MD. CERF is the nonprofit arm of Cenegenics® Medical Institute.

"There was a fair interest on my behalf and Dr. Klimas's behalf to look at probably one of the most comprehensive practices in age management medicine in the country over the last seven to nine years to formulate outcome measures retrospectively," said Ginzburg, who was the study's principal investigator.

The retrospective study surveyed 91 men and 97 women, ages 25 to 82, who were treated over a three-year period for clinically documented hormone deficiencies, testosterone and/or growth hormone. They were compared with controls to evaluate the treatment regimen's effect on body mass and whether there are differences among these groups.

Researchers established an organized database to determine outcome measures on bone density, Beck depression and lean body mass as well as review markers, such as PSAs (prostate-specific antigen to help mark prostate cell activity).

In phase one, positive results showed a significant improvement in the effects of Beck depression tests and quality-of-life tests with the use of hormone normalization along with improvement in lean body mass, decreased percentage of adipose tissue and increased bone density in men and women across a wide age range.

Cenegenics signed a two-year agreement with Ginzburg and Klimas for completing phases two and three.

Phase two will look at overall safety issues with regards to tumor formation as compared to a normal population.

"Phase three is going to be a more extensive analysis," Ginzburg said. "We really need larger numbers to make it significant in respect to the findings."

Dr. Enrique Ginzburg is a professor of surgery at the University of Miami - Miller School of Medicine's Divisions of Trauma and Surgical Critical Care. He is also the medical director at the International Health Center and co-director at the Neuroscience Intensive Care.

Dr. Nancy Klimas is a recognized leader and a champion of research in chronic fatigue syndrome. She is a professor of medicine, psychology, microbiology and immunology at the University of Miami - Miller School of Medicine and the Miami VA Medical Center.

Review the study at www.doveoa.com by clicking on the Journal of Multidisciplinary Healthcare link. For more information about Cenegenics, please visit www.cenegenics.com. Register for quick access to the informative Guide to Healthy Aging, Executive Summary and GQ article excerpt. To schedule an interview, please contact Ann Castro, Cenegenics Director of Public Relations: 702.953.1588 or acastro @ cenegenics.com.

About Cenegenics
Cenegenics® Medical Institute, recognized leading authority in age management medicine, has centers in Las Vegas, Nevada; Charleston, South Carolina; Boca Raton, Florida; Bloomington, Indiana; Dallas/Fort Worth, Texas; Atlanta, Georgia. More new centers are scheduled to open in major metropolitan areas throughout 2009. With an established presence in the medical community, Cenegenics uses a proactive approach based on solid science and comprehensive evaluation. Their established protocols have been recognized as the next generation of medical science, capturing global attention. Cenegenics offers CME-accredited physician training and certification opportunities in age management medicine via the nonprofit Cenegenics Education and Research Foundation (CERF). Headquartered in Las Vegas, Cenegenics serves more than 15,000 patients worldwide--1,500 are physicians and their families.

###

Read the full story at http://www.prweb.com/releases/cenegenics/research/prweb1467854.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Candice Lane MD Launches Hormone Health MD Plus: The First Doctor Bioidentical Hormone Blog
2. Breast Cancer Action Targets Yoplait in Think Before You Pink Campaign; Calls for Yogurt Without Artificial Hormones
3. Age alone should not be used to determine whether to treat prostate cancer with hormones
4. Hormone Therapy Not Best for Older Prostate Cancer Patients
5. Johns Hopkins researchers suppress hunger hormone
6. Acupuncture may hold promise for women with hormone disorder
7. UCLA and biotech company develop first blood test to measure key hormone that regulates iron
8. Monitoring Hormone May Improve Kidney Failure Outcomes
9. Thyroid Hormone May Boost Womens Alzheimers Risk
10. A hormone that enhances ones memory of happy faces
11. Menopause: Hot Flashes Can Be Reduced 90% without Hormones
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Hormone Normalization Shows Encouraging Effects In Documented Clinically Deficient Men/Women
(Date:8/22/2017)... Marina del Rey, CA (PRWEB) , ... August ... ... provider of revenue cycle management (RCM) solutions, announced recently the availability of a ... the HIM community in appreciation for their service to the healthcare industry. E/M ...
(Date:8/22/2017)... , ... August 22, 2017 , ... “To Walk Away”: ... on a B17 bomber named Edward Koontz. “To Walk Away” is the creation of ... who has published over two hundred manuscripts in chemistry and religion, as well as ...
(Date:8/22/2017)... ... , ... “Covert Awakening”: Walid’s spiritual journey from Islamic terrorist ... a consultant for the Intelligence Community. For more than ten years, she ... region. Julianne has written hundreds of reports for the US government analyzing ...
(Date:8/22/2017)... ... ... TopConsumerReviews.com recently gave a best-in-class 5-star rating to Energy NADH, a leader ... modern life continually makes more demands on time and energy, people are finding it ... in vicious high/low cycles and can also cause long term health issues. More people ...
(Date:8/21/2017)... ... 22, 2017 , ... PracticeMatch, a company that provides online resources , ... and advanced practitioners like nurse practitioners and physician assistants , will ... of this year. The online career fairs will allow job seekers to connect with ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)... Tenn. , July 31, 2017 Three Tru-D SmartUVC ... Yongsan, South Korea . Tru-D, short for "Total Room ... and operating rooms after an environmental services (ES) professional cleans the area ... ... "Although the ...
(Date:7/27/2017)... WARSAW, Ind., July 27, 2017  Zimmer Biomet Holdings, ... the quarter ended June 30, 2017.  The Company reported ... of 1.1% over the prior year period, and an ... approximately 240 basis points of contribution from the LDR ... from the second quarter of 2016, or 0.3% on ...
(Date:7/26/2017)... 26, 2017 Sancilio Pharmaceuticals Company, Inc. (SPCI) ... trial evaluating Altemia TM , an oral therapy for ... Cell Disease (SCD). The SCOT Trial, is a double-blind, ... safety of Altemia TM in pediatric patients aged ... IND 125274. "The ...
Breaking Medicine Technology: